AIM Vaccine Co., Ltd., a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

A nationwide surge in flu, COVID-19, RSV and norovirus infections is fueling concerns of a possible virus "quademic." Or is it just winter? The three respiratory viruses plus norovirus ...

This is the season for a rise in RSV cases. We talk to a local doctor on how to treat and stop the spread. Stay up-to-date: The latest headlines and weather from WPBF 25Click here to learn more.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

According to January 31, 2025 data posted by the Maricopa County Department of Public Health’s Respiratory Virus Surveillance ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

In preclinical animal trials, third-party testing results showed that AIM Vaccine's mRNA RSV vaccine achieved significantly higher levels of specific IgG antibody titers, live-virus neutralizing ...

HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory ...